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ABSTRACT
Despite great efforts taken to advance therapeutic measures for patients with 
glioblastoma, the clinical prognosis remains grim. The antiapoptotic Bcl-2 family 
protein Mcl-1 is overexpressed in glioblastoma and represents an important resistance 
factor to the BH-3 mimetic ABT263. 
In this study, we show that combined treatment with ABT263 and GX15-070 
overcomes apoptotic resistance in established glioblastoma cell lines, glioma stem-
like cells and primary cultures. Moreover, this treatment regimen also proves to 
be advantageous in vivo. On the molecular level, GX15-070 enhanced apoptosis by 
posttranslational down-regulation of the deubiquitinase, Usp9X, and the chaperone 
Bag3, leading to a sustained depletion of Mcl-1 protein levels. Moreover, knock-down 
of Usp9X or Bag3 depleted endogenous Mcl-1 protein levels and in turn enhanced 
apoptosis induced through Bcl-2/Bcl-xL inhibition. 
In conclusion, combined treatment with ABT263 and GX15-070 results in a 
significantly enhanced anti-cancer activity in vitro as well as in vivo in the setting 
of glioblastoma. Both drugs, ABT263 and GX15-070 have been evaluated in clinical 
studies which facilitates the translational aspect of taking this combinatorial approach 
to the clinical setting. Furthermore we present a novel mechanism by which GX15-
070 counteracts Mcl-1 expression which may lay a foundation for a novel target in 
cancer therapy.
INTRODUCTION
The prognosis for patients with glioblastoma is grim 
[1]. Great efforts have been taken to improve therapeutic 
means and thus survival. However, since the introduction 
of temozolomide, no further therapeutic approach followed 
to enter clinical application and to lead to a substantial 
improvement of the fate of glioma patients. This fact also 
holds true for many targeted therapies that were based on 
the identification of oncogenes, which were found to be 
frequently dysregulated in this disease [2-5]. The highly 
heterogeneous nature of glioblastoma and mechanisms 
of inherent or acquired resistance such as cross talk 
between different signaling pathways are likely to largely 
contribute to this phenomenon [6]. Therefore, strategies 
overcoming mechanisms of resistance are a logical and 
urgently needed step to advance the development of more 
efficient therapeutic approaches.
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The B-cell lymphoma-2 (Bcl-2) family proteins 
are important regulators of apoptosis and consist of pro- 
and anti-apoptotic members [7]. Dysregulation of this 
balanced system represents an important feature in cancer 
[8]. As a consequence targeted agents were developed to 
manipulate an anti-apoptotic dysbalance in the sense of 
shifting the cellular homeostasis of cancer cells towards 
apoptosis. ABT-compounds such as ABT737 or ABT263 
target the anti-apoptotic Bcl-2 family proteins Bcl-2, Bcl-
xL and Bcl-w and promote apoptosis by inhibiting the 
sequestration of the pro-apoptotic multidomain effectors 
BAX and BAK which subsequently oligomerize leading 
to mitochondrial outer membrane permeabilization and the 
release of cytochrome c into the cytosol. 
However, presence or even compensatory up-
regulation of myeloid cell leukemia 1 (Mcl-1), another 
anti-apoptotic member of the Bcl-2 family, was shown 
to confer resistance towards the treatment with ABT-
compounds [9, 10]. In addition, in silico analysis based 
on the TCGA data set revealed a 5-fold overexpression of 
Mcl-1 mRNA in glioblastoma when compared to normal 
brain (Supplementary Figure 1) suggesting that Mcl-
1 represents a valid target in this disease. GX15-070 is 
a small-molecule inhibitor of Mcl-1 and was shown to 
overcome Mcl-1-mediated resistance in oral carcinoma 
and murine melanoma cells [11]. Both, ABT-compounds 
as well as GX15-070, mimic the role of pro-apoptotic Bcl-
2 family proteins such as BAD, NOXA or PUMA sharing 
a conserved dimerization motif called Bcl-2 homology 3 
(BH3).
With this study, we examined whether combined 
treatment with the two BH3-mimetics ABT263 and 
GX15-070 may represent a valuable therapeutic approach 
in the setting of glioblastoma. Our data show that the 
combination therapy with ABT263 and GX15-070 yields 
a synergistic antiproliferative effect on established and 
glioma stem-like cells. In addition, in a heterotopic murine 
xenograft model this combination treatment resulted in 
a significant reduction in tumor size when compared to 
single-agent treatments or control and therefore holds 
promise as a novel therapeutic strategy in this disease. On 
the molecular level, we show that down-regulation of the 
Mcl-1 chaperone Bcl-2-associated athanogene domain 3 
(Bag3) and the deubiquitinase Ubiquitin-specific peptidase 
9, X-linked (Usp9X) represent a novel mechanism 
responsible for GX15-070-mediated down-regulation of 
Mcl-1.
RESULTS
Combined treatment with ABT263 and GX15-070 
yields a synergistic antiproliferative effect
To test our hypothesis that combined treatment with 
the Bcl-2 inhibitor ABT263 (Figure 1A) and the Mcl-1 
inhibitor GX15-070 (Figure 1A) yields a more favorable 
antineoplastic activity in glioblastoma when compared 
to single-agent treatments, we first examined effects on 
cellular proliferation by MTT assays. As shown in Figure 
1B, combined treatment with ABT263 and GX15-070 
resulted in a marked cooperative antiproliferative effect 
for all tested glioblastoma cells. Statistical analysis using 
the Bliss equation revealed that, except for NCH421K, in 
all other established glioblastoma cell lines, glioma stem-
like cells or primary cultures, the combination therapy 
with ABT263 and GX15-070 inhibited proliferation 
in a synergistic manner (Figure 1C). In NCH421K, the 
combination therapy yielded an additive effect. 
GX15-070 enhances the pro-apoptotic effect of 
ABT263 on cellular and molecular levels
As microscopic imaging showed, the 
antiproliferative effect of the combination treatment was 
accompanied by another prominent finding. Cellular 
morphology was observed to be markedly changed in 
cells treated with both agents displaying a reduction of 
cytoplasmic processes as the most pronounced feature 
(Figure 1D). The morphological appearance pointed 
towards apoptosis as mechanism. To clarify this suspicion, 
we performed staining for propidium iodide and flow 
cytometric analysis. Combined treatment with ABT263 
and GX15-070 resulted in a dose-dependent increase of 
the sub-G1 fraction (apoptotic cells) of U87MG, U87-
EGFRvIII, T98G, LN229 and U251 glioblastoma cells 
when compared to single-agent treatment or control 
(Figure 2A and Supplementary Figure 2). Similar results 
were found in two glioblastoma primary cultures - GS9-
6 and 2927T2 (Figure 2E). Staining for annexin V APC 
was performed, further confirming the enhancement of 
apoptosis by the combination therapy using an independent 
and more apoptosis-specific method (Figure 2B and 2C). 
To address the question whether the intrinsic pathway 
of apoptosis is involved, changes to the mitochondrial 
membrane potential were examined. Our data show that 
the combined treatment yields an enhanced reduction of 
the mitochondrial membrane potential in U87MG cells 
when compared to cells treated with either agent alone 
or solvent thus, underlining the role of intrinsic apoptosis 
(Figure 2D).
After having shown that the combination therapy 
with ABT263 and GX15-070 markedly enhances 
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Figure 1: Combined treatment with ABT263 and GX15-070 results in a synergistic antiproliferative effect across the 
majority of established glioma stem-like and primary cultured glioblastoma cells. A. chemical structures of ABT263 and 
GX15-070. B. U87MG, U87-EGFRvIII, LN229, T98G, glioma stem-like cells NCH421K, NCH644 and two glioblastoma primary cultures 
(human GS9-6 and murine MGPP-3) were treated with the indicated concentrations of ABT263 and GX15-070 or both agents under serum 
starvation (1.5% FBS). After 72 h, a MTT assay was performed. Data presented are representative for at least two independent experiments. 
Error bars: standard error of the mean (SEM). C. consolidated representation of qualitative combined antiproliferative effects of ABT263 
(A) and GX15-070 (G) on established glioma stem-like and primary cultured glioblastoma cells. The antiproliferative effect of the different 
drug combinations was assessed by an MTT assay prior to performing Bliss analysis in order to determine whether the combined treatments 
yielded synergisti, c: additive or antagonistic effects. The expected total response to the combination treatment was calculated as fractional 
response to drug A (Fa) + fractional response to drug B (Fb) - Fa x Fb. If the ratio of the actual total response and the expected total response 
equaled 0.9 to 1.1, additivity was assumed. If this quotient was less than 0.9, the effect was described as antagonistic. Synergism was stated 
if the quotient was greater than 1.1. D. representative microphotographs of U87-EGFRvIII and T98G cells at indicated magnifications after 
24 h of treatment with ABT263, GX15-070 or both. Morphological changes such as a rounding of cells are commonly seen after treatment 
with both agents. 
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Figure 2: Combined treatment with ABT263 and GX15-070 results in an enhanced induction of apoptosis. A. 
representative histograms of U87MG, U87-EGFRvIII, T98G, LN229 and U251 glioblastoma cells that were treated for 48 h with the 
indicated concentrations of ABT263, GX15-070, both, or solvent prior to staining with propidium iodide and flow cytometric analysis. B. 
quantitative representation of annexin V-positive U87MG and LN229 glioblastoma cells treated for 72 h with ABT263, GX15-070, both, 
or solvent at indicated concentrations. Columns, means of three serial measurements. Bars, SD. C. representative histograms of annexin 
V-positive U87MG and LN229 glioblastoma cells treated as described for Figure 2B. D. representative histograms of U87MG cells that 
were treated for 24 h with ABT263, GX15-070, both, or solvent prior to staining with JC-1 and flow cytometric analysis. Cells treated 
with the mitochondria depolarizing agent carbonylcyanide m-chlorophenylhydrazone (CCCP) served as a positive control. E. quantitative 
representation of the fraction of sub-G1 cells. GS9-6 and 2927T2 glioblastoma primary cultures were treated and analyzed as described for 
Figure 2A. Columns, means of three serial measurements. Bars, SD. 
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the induction of apoptosis on the cellular level we 
examined the response at the molecular level. Therefore, 
Western blot analyses for activation of caspases 9 and 
3 were conducted in U87MG, LN229, T98G and U373 
glioblastoma cells. In all these cell lines, the combination 
therapy resulted in markedly enhanced cleavage of 
initiator caspase 9 and effector caspase 3 (Figure 3A-3D). 
Figure 3: Combined treatment with ABT263 and GX15-070 results in enhanced cleavage of caspases 9 and 3 and 
enhanced inhibition of anchorage-independent growth as well as in vivo tumor formation. A.-D. U87MG A. LN229 B. 
T98G C. and U373 D. glioblastoma cells were treated for 7 h with ABT263, GX15-070, both agents or solvent under serum starvation. 
Whole-cell extracts were examined by Western blot for caspase 9 (C9) and cleaved caspase 3 (cC3). Actin Western blot analysis was 
performed to confirm equal protein loading. E. U87-EGFRvIII and LN229 cells were grown in 0.35% agarose in DMEM supplemented 
with 10% FBS for 21 d. Representative photographic images are shown. F. quantitative representation of the number of colonies formed. 
Only colonies with an area  >  625 µm2 were counted. Experiments were done in duplicate and repeated once (n  =  2). Columns, mean of 
the number of colonies counted for one representative experiment. Bars, SEM. G. U87-EGFRvIII cells were pretreated as indicated in the 
materials and methods section and implanted subcutaneously in mice. Scatter plot showing 9 tumors per group. Line, mean; bars, SEM. 
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GX15-070 enhances the inhibitory effect of 
ABT263 on colony-forming ability in vitro and on 
tumor formation in vivo
Next, we investigated whether the combination 
therapy is superior in terms of inhibiting anchorage-
independent growth. For this purpose, a soft agar assay 
was used in which U87-EGFRvIII and LN229 cells 
were treated with 1 µM ABT263, 0.5 µM GX15-070, 
both agents or solvent. After 21 days of continuous 
drug exposure, representative images were taken and 
analysed. Only colonies larger than 625 µm2 were 
counted. Typically, both cell lines formed a high number 
of colonies under control conditions (Figure 3E and 
3F). While treatment with either ABT263 or GX15-070 
alone resulted in minor reductions of colony formation, 
concomitant treatment with both compounds greatly 
reduced anchorage-independent growth in both cell lines 
(Figure 3E and 3F). This effect was less pronounced in 
U87-EGFRvIII cells that harbor the constitutively active 
EGFRvIII and have a particularly resistant phenotype. 
Figure 4: Down-regulation of Bag3 sensitizes for ABT263-mediated apoptosis. A.-B. LN229 A. and T98G B. glioblastoma 
cells were treated for 24 and 48 h with increasing concentrations of GX15-070. Whole-cell extracts were examined by Western blot for 
Bag3, Mcl-1, Bcl-2 and Bcl-xL. Actin Western blot analysis was performed to confirm equal protein loading. C. LN229 glioblastoma cells 
were treated with Bag3-siRNA or non-targeting (n.t.)–siRNA as described in the materials and methods section prior to treatment with 
ABT263 at indicated concentrations for 7 h. Whole-cell extracts were examined by Western blot for Bag3 and Mcl-1. Actin served as 
loading control. D. LN229 glioblastoma cells were treated as described for Figure 4C prior to collecting whole-cell extracts and performing 
Western blot analysis for caspases 9 (CP9) and 3 (cCP3). E. representative histograms of LN229 glioblastoma cells treated with n.t.-siRNA 
or Bag3-siRNA prior to treatment with ABT263 for 24 h. Then cells were stained for PI and subjected to flow cytometric analysis. The 
fraction of sub-G1 cells was determined. 
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Further, we examined whether combined treatment 
with GX15-070 and ABT263 also impairs tumor formation 
in an in vivo setting that allows for an interaction between 
the tumor and surrounding tissue, including neoplastic 
features such as neo-angiogenesis. Therefore, we 
implanted pretreated U87-EGFRvIII cells subcutaneously 
into the flanks of SCID SHO mice and determined tumor 
volumes once tumors formed. As outlined in Figure 3G, 
combined treatment with ABT263 and GX15-070 did 
not prevent tumor formation but resulted in a marked 
reduction of tumor volumes. 
Treatment with GX15-070 results in down-
regulation of the Mcl-1-chaperone Bag3 and 
subsequent loss of Mcl-1 and Bcl-2
Next, we dissected the molecular events responsible 
for the GX15-070-mediated sensitization towards 
ABT263. It is known that GX15-070 inhibits Mcl-1 [11]. 
However, the exact mechanism is not fully understood. 
Bag3 has been shown to stabilize Mcl-1 [12]. In the same 
study, silencing of Bag3 increased the response to ABT263 
in different cancer cell lines not including gliomas. Our 
data show that treatment with GX15-070 results in a dose-
dependent down-regulation of Bag3 in LN229 and T98G 
glioblastoma cells (Figure 4A and 4B). Moreover, this 
finding is accompanied by a pronounced down-regulation 
of Mcl-1 and Bcl-2, suggesting that GX15-070-mediated 
down-regulation of Bag3 leads to loss of Mcl-1 and Bcl-
2 (Figure 4A and 4B). Notably, the expression of Bcl-xL 
was not altered. 
Down-regulation of Bag3 sensitizes for ABT263-
mediated apoptosis by decreasing Mcl-1 protein 
levels in glioblastoma cells
To address the question whether down-regulation of 
Bag3 by GX15-070 sensitizes glioblastoma cells towards 
ABT263-mediated apoptosis, we performed knock-
down experiments silencing Bag3 prior to treatment with 
increasing concentrations of ABT263. Treatment with 
Bag3-siRNA resulted in an efficient down-regulation 
of Bag3 expression in LN229 cells (Figure 4C). In 
addition, up-regulation of the anti-apoptotic Bcl-2 family 
protein Mcl-1, following treatment with ABT263, was 
counteracted by silencing Bag3. Moreover, knock-down 
of Bag3 markedly enhanced cleavage of caspases 9 and 3 
upon treatment with ABT263, compared to cells subjected 
to single- or combined treatment with non-targeting 
siRNA and ABT263 (Figure 4D). These findings were 
confirmed on the cellular level by staining with PI and 
subsequent flow cytometric analysis. Silencing of Bag3 
combined with ABT263-treatment significantly increased 
the fraction of sub-G1 cells compared to cells treated with 
non-targeting siRNA plus ABT263 or Bag3-siRNA alone 
(Figure 4E). 
To examine whether down-regulation of Mcl-1 is 
sufficient to sensitize glioma cells for ABT263-mediated 
apoptosis, we performed knock-down experiments 
targeting Mcl-1 in LN229 glioblastoma cells. Silencing 
Mcl-1 alone resulted in a marked decrease but not a 
total suppression of Bag3 (Supplementary Figure 3A). 
However, knock-down of Mcl-1 combined with treatment 
with ABT263 yielded a complete suppression of Bag3. 
This finding was accompanied by an enhanced cleavage 
of caspases 9 and 3 as well as PARP and an increase in the 
fraction of sub-G1 cells (Supplementary Figure 3B and 
C). Silencing of Mcl-1 alone resulted in a greater increase 
of the fraction of sub-G1 cells compared to silencing of 
Bag3 alone, suggesting that down-regulation of Mcl-1 is 
ultimately the critical event for enhancement of responses 
to ABT263, including apoptosis. Again, expression of Bcl-
xL was not markedly altered.
Treatment with GX15-070 results in down-
regulation of the deubiquitinase Usp9X
Usp9X modulates Mcl-1 levels and counteracts 
apoptosis in cancer cells [13]. Given that GX15-070 
suppresses Mcl-1, we examined whether it regulates 
the expression of Usp9X. In LN229 and T98G cells, 
we detected a strong reduction in Usp9X levels after 24 
h and 48 h of treatment with increasing concentrations 
of GX15-070 (Figure 5A-5B). In contrast, Noxa levels 
revealed a slight up-regulation in T98G cells treated 
with GX15-070 (Figure 5B). Next we silenced Usp9X 
in LN229 glioblastoma cells to determine the impact of 
Usp9X on the chaperone Bag3 as well as initiator- and 
effector caspases. Silencing of Usp9X by siRNA results 
in down-regulation of Usp9X protein levels, concomitant 
suppression of Bag3, strong activation of caspase-9/-3 
and apoptosis induction (Figure 5C-5D), suggesting 
that suppression of Usp9X is a pivotal regulator of 
intrinsic apoptosis and a potent sensitizer for intrinsic 
apoptotic stimuli in TP53-mutated glioblastoma cells. 
Consistently, LN229 cells with silenced Usp9X showed a 
greater sensitivity to ABT263 as evidenced by enhanced 
activation of caspase-9/-3 and a pronounced reduction in 
cellular viability compared to LN229 cells transfected with 
non-targeting siRNA (Figure 5E-5F). Since suppression 
of Usp9X significantly enhances apoptosis induced by 
ABT263, we determined the effects of ABT263 on Usp9X 
and Bag3 protein levels. U251 cells were transfected with 
non-targeting or Usp9X-specific siRNA and treated with 
2 μM ABT263 (Figure 5G). While U251 cells transfected 
with non-targeting siRNA showed an increase in both 
Usp9X and Bag3 protein levels after treatment with 
ABT263, this induction was attenuated in cells transfected 
with Usp9X-siRNA (Figure 5G). Thus, ABT263-mediated 
induction of both Usp9X and Bag3 is inhibited by 
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Figure 5: GX15-070 down-regulates the deubiquitinase Usp9X which sensitizes cells for ABT263-mediated apoptosis. 
A.-B. LN229 A. and T98G B. glioblastoma cells were treated for 24 and 48 h with increasing concentrations of GX15-070. Whole-
cell extracts were examined by Western blot for Usp9X and Noxa. Actin Western blot analysis was performed to confirm equal protein 
loading. C. LN229 glioblastoma cells were treated with Usp9X-siRNA or non-targeting (n.t.)–siRNA prior to Western blot analysis for 
Usp9X, Bag3, caspase 9 (C9) and cleaved caspase 3 (cC3). Actin Western blot analysis was performed to confirm equal protein loading. 
D. representative histograms of LN229 glioblastoma cells treated with Usp9X-siRNA or n.t.–siRNA prior to staining with annexin V/PI 
and flow cytometric analysis. E. LN229 glioblastoma cells were treated with Usp9X-siRNA or n.t.–siRNA prior to treatment with ABT263 
at indicated concentrations for 24 h. Whole-cell extracts were examined by Western blot for caspase 9 (C9) and cleaved caspase 3 (cC3). 
Actin served as a loading control. F. LN229 glioblastoma cells were transfected either with Usp9X-siRNA or n.t.–siRNA. Treatment with 
ABT263 or solvent was performed for 24 h prior to staining for annexin V/PI and flow cytometric analysis. Columns, means of viable cells. 
Bars, SEM. G. U251 glioblastoma cells were treated either with Usp9X-siRNA or n.t.–siRNA. Treatment with ABT263 or solvent was 
performed for 48 h. Whole-cell extracts were examined by Western blot for Usp9X and Bag3. 14-3-3 Western blot analysis was performed 
to confirm equal protein loading. H. LN229 cells were treated for 7 or 24 h with increasing concentrations of GX15-070 or solvent. Cells 
were collected and RNA isolated prior to performing rtPCR for Usp9X, Bag3 and Mcl-1. I. LN229 glioblastoma cells were treated with 
the protein synthesis inhibitor cycloheximide (10 μg/ml) in the presence or absence of GX15-070 (1 μM) for the indicated time points. 
Western blot analysis was performed for Usp9X and Bag3. 14-3-3 expression was determined to confirm equal protein loading. J. LN229 
glioblastoma cells were treated with or without the proteasome inhibitor MG132 (10 μM) in the presence or absence of the combination of 
ABT263 (0.5 μM) and GX15-070 (1 μM) for 5 h. Western blot analysis was performed for Usp9X, Bag3 and Mcl-1. 14-3-3 expression was 
determined to confirm equal protein loading. 
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Figure 6: Combined treatment with ABT263 and GX15-070 results in an enhanced inhibition of tumor growth in vivo. 
1x106 U251 glioblastoma cells were implanted subcutaneously. After tumor formation animals were treated intraperitoneally with vehicle 
(n  =  9 tumors), GX15-070 (3 mg/kg; n  =  12 tumors), ABT263 (50 mg/kg; n  =  9 tumors) or both agents (n  =  12 tumors) twice a week 
for 3 weeks. Data are presented as mean and SEM. A. tumor growth curves showing the fold increase in tumor size for each treatment 
group. B. representative photographs of the tumors. C. quantification and statistical analysis of the different treatment groups 41 days after 
tumor implantation. The Mann-Whitney U-test was used for statistical analysis and a p-value of less than 0.05 was considered statistically 
significant. D. microphotographs showing the histological morphology of representative tumors treated as indicated after staining for 
hematoxylin and eosin (H&E left panel) or Ki-67 (right panel). Magnification, x40; scale bar, 100 μm. E. representative microphotographs 
showing the histological morphology (H&E staining) of the indicated organs among representative animals receiving treatment either with 
vehicle or the combination of ABT263 and GX15-070. Magnification, x40; scale bar, 100 μm. 
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interference with Usp9X levels, suggesting that Usp9X is 
upstream of Bag3 and that it is implicated in the regulation 
of its expression. Next, we examined how GX15-070 
regulates the expression levels of both Usp9X and Bag3. 
Therefore, LN229 cells were treated with cycloheximide 
in the presence or absence of GX15-070. LN229 cells 
treated with the combination of cycloheximide and GX15-
070 showed a significantly lower expression of both 
Bag3 and Usp9X, indicating that GX15-070 most likely 
regulates Bag3 and Usp9X in a posttranslational manner, 
potentially involving enhanced proteasomal degradation 
(Figure 5I). To explore the mechanisms of enhanced 
proteasomal degradation LN229 cells were treated with 
MG132, ABT263/GX15-070 or the triple therapy of 
ABT263/GX15-070/MG132. While the combination of 
ABT263 and GX15-070 depleted both Usp9X and Bag3 
levels, the triple therapy partially rescued the expression 
of Usp9X and Bag3 (Figure 5J). To determine whether 
GX15-070 regulates Usp9X, Bag3 or Mcl-1 expression 
on the transcriptional level, we conducted real-time PCR 
analyses and found that in LN229 cells Usp9X mRNA 
levels were only minimally affected by GX15-070 at the 
indicated time points (Figure 5H). Bag3 and Mcl-1 mRNA 
levels were markedly increased by GX15-070 treatment in 
LN229 cells indicating a compensatory response. Overall, 
down-regulation of Usp9X, Bag3 and Mcl-1 on the protein 
level does not seem to be transcriptionally mediated.
Treatment with GX15-070 enhances the 
antineoplastic effect of ABT263 in vivo
To assess the therapeutic efficacy of this 
combination therapy in vivo, U251 glioblastoma cells 
were implanted subcutaneously. Once tumors formed, the 
mice were randomized and treated with ABT263 (50 mg/
kg), GX15-070 (3 mg/kg), both agents or solvent. Under 
these conditions, animals that received the combination 
treatment had statistically significantly smaller tumors 
than animals treated with vehicle, ABT263 or GX15-070 
alone (Figure 6A-6C). Remarkably, animals treated with 
the drug combination showed tumor regression, indicating 
that the combination therapy did not only affect tumor 
proliferation it also impacted tumor cell death in vivo 
(Figure 6A). On histological sections we found that tumors 
treated with ABT263/GX15-070 displayed a higher rate 
of dead cells than the single and vehicle treated tumors 
(Figure 6D). In addition, proliferation was markedly 
reduced in tumors treated with the combination therapy 
as reflected by a reduced staining for Ki-67 (Figure 6D). 
Histological analysis showed no tissue alterations in brain, 
lung, kidney, heart, liver, spleen, intestine or pancreas that 
may indicate organo-toxic effects (Figure 6E). 
DISCUSSION
Evasion from apoptosis is a characteristic feature 
of cancer cells and is fundamental for drug resistance, 
especially in therapy refractory neoplastic diseases such 
as glioblastoma [14]. Therefore, it is of great importance 
to understand how apoptosis is being avoided and to 
develop strategies to overcome apoptotic resistance. 
Dysregulation of the Bcl-2 family proteins, resulting in 
an upward shift of the apoptotic threshold, is frequently 
encountered in cancer [8]. As a consequence therapeutic 
compounds (i.e. ABT737, ABT263) selectively targeting 
anti-apoptotic Bcl-2 family members were developed. 
However, Mcl-1 was found to confer resistance towards 
these agents [9, 10]. Therefore, a multi-targeting approach 
including Mcl-1-targeted BH3-mimetics seems like a valid 
strategy to overcome ABT-related drug resistance. Here, 
we describe a novel drug combination for the treatment 
of glioblastoma that consists of the orally available Bcl-2/
Bcl-xL inhibitor ABT263 and the Mcl-1 inhibitor GX15-
070. Both are currently being evaluated in clinical trials. 
In phase I clinical trials, single-agent treatment with 
ABT263 has been shown to have a favorable safety profile 
and to be well tolerated in patients with small-cell lung 
cancer or relapsed chronic lymphocytic leukemia [15-
17]. Moreover, in a recently published phase II clinical 
trial, combined treatment with ABT263 and rituximab 
was reported to result in higher response rates when 
compared to treatment with rituximab alone in patients 
with previously untreated chronic lymphocytic leukemia 
[18]. Similarly, GX15-070 has been studied in phase I 
and phase II clinical trials for the treatment of patients 
with lymphoma, small-cell lung cancer, non-small-cell 
lung cancer and other solid tumors as a single-agent or 
in combination with different anti-neoplastic agents [19-
22]. The treatment with GX15-070 was reported to be 
generally well tolerated and improved efficacy was stated 
by some of the studies [20, 21]. In our study, combined 
treatment with ABT263 and GX15-070 yielded a 
synergistic antiproliferative effect on gliobastoma cells. It 
is tempting to speculate whether our combination therapy 
may have a positive impact on standard of care treatments 
for glioblastoma, such as radiation and/or temozolomide. 
Since ABT263 and GX15-070 act at the level of the anti-
apoptotic Bcl-2 family members it seemed promising to 
examine whether combined treatment enhances apoptosis. 
Consistently, established glioblastoma cell lines, stem cell-
like glioma cells as well as primary cultures displayed 
hallmarks of apoptotic cell death, such as enhanced 
staining for annexin V, loss of mitochondrial membrane 
potential and activation of initiator and effector caspases. 
These findings are in accordance with the current literature 
[23-27].
While our initial hypothesis was that GX15-
070 interferes with Mcl-1 activity, but not necessarily 
modulates its expression levels, we found that GX15-070 
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by itself markedly reduced the expression levels of Mcl-1 
in glioblastoma cells, which in turn would be expected to 
attenuate ABT263-mediated up-regulation of Mcl-1 and 
thus drive susceptibility of glioma cells to BH3-mimetics. 
While Mcl-1 expression is known to be regulated through 
posttranscriptional and posttranslational mechanisms, 
there are also instances in which Mcl-1 is regulated at the 
level of transcription, e.g. through activating transcription 
factor 5 [28]. Therefore, we first assessed whether Mcl-
1 mRNA levels are significantly affected by GX15-070 
treatment. Our findings suggested that in glioblastoma 
cells there is a marked increase of Mcl-1 mRNA levels 
in response to increasing concentrations of GX15-070. 
However, this increase in mRNA did not correspond 
to the observed reduction of Mcl-1 protein. Thus, we 
hypothesized that GX15-070 affects Mcl-1 levels primarily 
posttranslationally. Several factors are known to interact 
with and stabilize Mcl-1 protein, e.g. Usp9X [13], Bag3 
[12] and MULE [29]. GX15-070 did not greatly affect 
mRNA levels of Usp9X and even increased Bag3 mRNA 
expression however, protein levels were suppressed. 
This finding reinforced the notion that GX15-070 affects 
Mcl-1 protein levels through inhibition of its interacting 
partners, Usp9X and Bag3. While Usp9X belongs to the 
family of deubiquitinases and promotes Mcl-1 stability 
by removing ubiquitin chains from Mcl-1 [13], Bag3 
most likely enhances Mcl-1 levels through its function as 
chaperone. However, both molecules drive Mcl-1 to high 
levels within tumor cells. Akin to Mcl-1, both Usp9X and 
Bag3 are expressed at higher levels in malignant tissues 
[30, 31]. Bag3 protein expression is increased in both 
low- and high-grade astrocytic gliomas, with the highest 
expression levels found in glioblastoma [30]. Knock-down 
of Bag3 caused apoptosis in a rat glioma model. Although 
Festa et al. have certainly established a role for Bag3 as 
a therapeutic target; they have not established Mcl-1 as 
a downstream mediator of Bag3 in malignant glioma. 
Moreover, GX15-070 has not been demonstrated before to 
modulate the expression levels of Bag3. Thus, to the best 
of our knowledge our present report is the first to highlight 
a regulation of Bag3 by GX15-070. In addition, drugs that 
modulate the expression or even specifically bind to Bag3 
have not been described. However, given the potential 
therapeutic potency as demonstrated by our knock-down 
experiments of Bag3 and the fact that Bag3 is up-regulated 
in malignant tissue, it may be a worthwhile approach to 
unravel or design molecules targeting Bag3. 
Concerning Usp9X, the present literature 
suggests that while Usp9X has a pivotal role during the 
development of the nervous system [32], its expression 
declines in the mature brain, suggesting that it is a specific 
therapeutic target for primary brain tumors. There is 
minimal information on Usp9X signaling in glioblastoma 
cells. Usp9X has not been targeted for clinical therapy in 
malignant glioma. Given that we and others demonstrated 
an apoptosis-inducing effect on glioblastoma cells 
subsequent to Usp9X-silencing [33], we believe that it 
is worthwhile considering Usp9X as a future therapeutic 
target. Thus far, it appears that Mcl-1 is one of the major 
effectors of Usp9X, but recent reports suggest that Usp9X 
may have further therapeutic implications. A recent study 
focused on Usp9X in the context of a frequent prostate 
carcinoma-related genetic translocation (TMPRSS2-
ERG) [34] that facilitates tumor growth and thus not only 
represents a diagnostic aid, but also a potential therapeutic 
target. VCaP cells harbor the TMPRSS2-ERG gene fusion 
and in turn they express significant levels of ERG, which 
is stabilized by Usp9X. Interfering with Usp9X function 
by chemical inhibition through the deubiquitinase 
inhibitor, WP1130, results in proteasomal degradation 
of ERG and impaired growth of tumor cells exhibiting 
this genetic alteration in vivo [34]. Another compound 
that reduces Usp9X levels is Pemetrexed. While Usp9X 
was suppressed by Pemetrexed, the pro-apoptotic protein 
Noxa was inversely regulated. Based on this model 
system, Pemetrexed-mediated increase in Noxa resulted in 
suppression of Usp9X and subsequent depletion of Mcl-1 
protein levels, rendering lung adenocarcinoma cells more 
sensitive to apoptotic stimuli. In our study, we demonstrate 
a novel mechanism by which GX15-070 elicits its anti-
cancer properties beyond the inhibitory effects on Mcl-1. 
Our data show that GX15-070 was remarkably efficacious 
in suppressing Usp9X protein levels in glioblastoma cells. 
In the setting of the above mentioned studies it is tempting 
to speculate whether GX15-070 may be useful in other 
malignancies, in particular in advanced stage prostate 
cancer, displaying the TMPRSS2-ERG gene fusion. 
Another recent report links Usp9X to Beclin-1, a gene 
that is known as a tumor suppressor and a modulator of 
autophagy [35]. Elgendy et al. demonstrated that Beclin 1 
interacts with Usp9X in a region related to the binding of 
Mcl-1 to Usp9X [35], linking Usp9X to both autophagy 
as well as intrinsic apoptosis. Although tumor cells 
harbored high levels of Mcl-1 and low levels of Beclin 
1 – a relationship inversely found in normal cells – a more 
detailed understanding of how Usp9X regulates both 
apoptosis and autophagy is necessary.
Our results show that knock-down of both Bag3 
and Usp9X leads to a depletion of Mcl-1 protein levels 
in glioblastoma cells and rendered them highly sensitive 
to ABT263. These findings are in line with reports from 
other groups, showing that knock-down of Usp9X or 
Bag3 sensitize tumor cells to ABT737. It is notable that 
our study is the first to demonstrate that single knock-
down of both Bag3 and Usp9X are sufficient to sensitize 
glioblastoma cells to BH3-mimetics. Thus, targeting 
both Bag3 and Usp9X may represent novel approaches 
to overcome intrinsic and potentially extrinsic apoptotic 
resistance in glioblastoma. GX15-070 is unique in that 
it suppressed Bag3 and Usp9X levels simultaneously in 
glioblastoma cells independently of their TP53 status, 
which most likely further enhanced GX15-070 mediated 
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susceptibility to BH3-mimetics.
We further showed that the combination therapy of 
ABT263 and GX15-070 inhibited anchorage-independent 
growth of glioblastoma cells including therapy-resistant 
U87-EGFRvIII cells. Moreover, we found that the 
combination treatment significantly impaired in vivo 
growth of U87-EGFRvIII cells. These findings are 
promising as they suggest a proof-of-principle that 
the combined inhibition of Mcl-1-related chaperones 
in combination with selective Bcl-2/Bcl-xL inhibitors 
may be a suitable approach to combat the most resistant 
phenotypes of gliomas and potentially other entities. 
Finally, we tested whether this drug combination is 
more effective than the single drugs alone in a heterotopic 
model of murine glioma. While animals receiving either 
ABT263 or GX15-070 revealed a subtle reduction in 
tumor growth, the combination treatment was significantly 
more active than the vehicle treated control, ABT263 or 
GX15-070 suggesting that this combined strategy exerts 
enhanced anti-glioma activity in vivo. These findings 
are consistent with previous studies, in which other 
compounds, such as mTOR/PI3K inhibitors [27] or 
Inhibitor of Apoptosis protein suppressors [36], were used 
to enhance the activity of BH3-mimetics in vivo. However, 
the approach presented here is unique in that our proposed 
combination therapy not only affects Mcl-1 itself, but 
also controls the expression levels of two major Mcl-1 
interacting proteins, namely Usp9X and Bag3. We propose 
that compounds, affecting the Mcl-1 interacting protein 
family might be a welcome addition to the treatment 
repertoire for treatment resistant malignancies, such as 
glioblastoma.
MATERIALS AND METHODS
Ethics statement
All procedures were in accordance with Animal 
Welfare Regulations and approved by the Institutional 
Animal Care and Use Committee at the Columbia 
University Medical Center. The study was reviewed and 
approved by the institutional review board at the Columbia 
University Medical Center. 
Reagents
ABT263 and GX15-070 were from Selleckchem 
(Houston, TX, U.S.A.). A 10 mM working solution 
in dimethylsulfoxide (DMSO) was prepared for both 
reagents prior to storage at -20°C. Final concentrations of 
DMSO were below 0.1% (v/v).
Cell cultures and growth conditions
U87MG, LN229, U373, U251 and T98G human 
glioblastoma cell lines were obtained from the American 
Type Culture Collection (Manassas, VA, U.S.A.). NCH644 
and NCH421K stem cell-like glioma cells were obtained 
from Cell Line Services (CLS, Heidelberg, Germany). The 
identities of the glioblastoma cell lines we purchased were 
confirmed by the respective source of purchase except for 
U373, which is no longer verified by the ATCC. U87-
EGFRvIII cells were kindly provided by Dr. Frank Furnari 
(Ludwig Institute for Cancer Research, La Jolla, CA, 
U.S.A.). GS9-6 [28] and 2927T2 are primary neurosphere 
stem-like glioma cells derived at the University of 
Massachusetts (Worcester, MA, U.S.A.). The 2927T2 line 
was derived from a recurrent tumor. The MGPP-3 (p53-/-, 
PTEN+/+) is a murine proneural glioblastoma cell which 
was kindly provided by Dr. Peter Canoll. All cells were 
cultured as previously described [37]. 
Cell viability assays
In order to examine cellular proliferation, 3-[4, 
5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide 
(MTT) assays were performed as previously described 
[37].
Measurement of apoptosis and mitochondrial 
membrane potential
For annexin V APC staining the APC annexin V 
Apoptosis Detection Kit (BD Pharmingen, U.S.A.) was 
used according to the manufacturer’s instructions. For PI 
staining, cells were resuspended in 300 µl PBS and fixated 
by adding 1000 µl ice-cold ethanol prior to incubation 
over night at 4ºC. Then the cells were centrifuged at 1800 
rpm, the supernatant was removed and 400 µl PI/RNase 
staining solution (Cell signaling technology, Danvers, 
MA, U.S.A.) were added prior to incubation for 15 min at 
RT and flow cytometric analysis. 
To detect intrinsic apoptosis staining for JC-1 was 
performed according to the manufacturer’s instructions 
using the MitoProbeTM JC-1 assay kit for flow cytometry 
(Molecular Probes®, Life Technologies) [38]. The data 
were analysed with the FlowJo software (version 8.7.1; 
Tree Star, Ashland, OR, U.S.A.).
Soft agar assay
Anchorage-independent growth was examined 
as previously described [37]. Colonies with an area 
exceeding 625 µm2 were counted. Analysis was performed 
using the NIH ImageJ software (Bethesda, Maryland; 
http://imagej.nih.gov/ij).
Oncotarget14519www.impactjournals.com/oncotarget
In vivo tumorigenicity assay
Effects on tumorigenesis in vivo were examined 
as previously described [39]. U87-EGFRvIII cells were 
treated with ABT263 (2 μM), GX15-070 (2 μM), the 
combination of both or solvent for 2 h prior to collection 
and subcutaneous implantation of 1 x 106 cells into the 
flanks of 6-8 week-old SCID SHO mice. Tumor formation 
was closely monitored.
Subcutaneous xenograft model
2 x 106 U251 cells were implanted subcutaneously 
into the flanks of 6-8 week-old SCID SHO mice. 
Measurements were performed with a caliper and tumor 
sizes were calculated as (length x width2)/2. Treatment was 
performed intraperitoneally twice a week for 3 weeks. For 
intraperitoneal application ABT263 and GX15-070 were 
dissolved in 80% Cremophor EL (SIGMA, St. Louis, MO) 
and 20% Ethanol (Pharmco-Aaper, Brookfield,CT) (v/v). 
Western blot analysis
Specific protein expression in cell lines was 
determined by Western blot analysis as described before 
[27] using the following primary antibodies: Mcl-1 (1:500; 
CST: Cell Signaling Technology, Danvers, MA), human 
caspase-9 (1:1,000; CST), cleaved caspase-3 (1:250; 
CST), cleaved PARP (Asp214, 1:1000; CST), Bcl-xL 
(1:500; CST), Usp9X (1:1000; CST), Noxa (1:500, clone 
114C307; Calbiochem), β-actin (1:2,000, clone AC15; 
Sigma Aldrich), Bag3 (1:500; Abcam, Cambridge, MA). 
14-3-3 (1:1,000) and secondary HRP-linked antibodies 
were purchased from Santa Cruz Biotechnology. 
Transfections of siRNAs
SignalSilence® Usp9X siRNA I #6308 was 
purchased from CST. Non-targeting siRNA-pool 
(ON-TARGETplus Non-targeting Pool, # D-001810-
10-05) and siRNA against Bag-3 (SMARTpool: ON-
TARGETplus Bag3 siRNA, L-011957-00-0005) and 
Mcl-1 (SMARTpool: ON-TARGETplus Mcl-1 siRNA, 
L-004501-00-0005) were purchased from Thermo Fisher 
Scientific (Pittsburgh, PA) and transfected as previously 
described [38].
Real-time PCR and cDNA synthesis
RT-PCR was performed as described before [27] 
using the following primers: Usp9x forward: GTG TCA 
GTT CGT CTT GCT CAG C; Usp9X reverse: GCT GTA 
ACG ACC CAC ATC CTG A; Bag3 forward: TGC CAG 
AAA CCA CTC AGC CAG A; Bag3 reverse: TGA GGA 
TGA GCA GTC AGA GGC A; Mcl-1 forward: CCA AGA 
AAG CTG CAT CGA ACC AT; Mcl-1 reverse: CAG CAC 
ATT CCT GAT GCC ACC T; GAPDH forward: GTC TCC 
TCT GAC TTC AAC AGC G and GAPDH reverse: ACC 
ACC CTG TTG CTG TAG CCA A. 
Histological analysis
Subcutaneous tumors and samples from organs 
were extracted from SCID SHO mice and fixed for at 
least 24 hours in 10% PBS-buffered formalin. Then 
tissues were embedded in paraffin and 4 μm thick sections 
were cut prior to staining with hematoxylin and eosin. 
Microphotographs were taken at x40 magnification. 
Statistical analysis
Statistical significance was assessed by Mann-
Whitney U-test using Prism version 5.04 (GraphPad, La 
Jolla, CA, U.S.A.). A p≤0.05 was considered statistically 
significant. Bliss analysis was performed to detect 
synergistic, additive or antagonistic effects as previously 
described [37].
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